Pulmonary complications of transplantation develop as a consequence of epithelial injury and/or the alveolar response to infection. Injury could result from chemotherapy or radiation therapy used as part of the conditioning regimen 1 or could be related to infections common in the peritransplant period, including fungi, cytomegalovirus, respiratory viruses, bacteria, and Pneumocystis carinii.
2 Alveolar hemorrhage could result from pulmonary edema arising from cardiac dysfunction or acute respiratory distress syndrome. In certain populations, alveolar hemorrhage might be a manifestation of graft-versushost disease (GVHD) or an immune-associated event. 3, 4 Diffuse alveolar hemorrhage (DAH) traditionally has been described as a clinical syndrome with acute onset of alveolar infiltrates and hypoxemia, yielding a progressively bloody alveolar lavage. 5, 6 This occurs in the absence of a discernable infectious etiology. Infection-and noninfection-associated DAH clinically are indistinguishable. Clinical features include dyspnea or a cough, an abnormal chest X-ray showing subtle alveolar infiltrates, bleeding, and hypoxia usually with fever, but with the absence of infectious etiology. 7 The median time of onset of symptoms is 2-3 weeks after transplantation (range 1-8). The incidence of DAH in autologous stem cell transplants has been reported to range from 1 to 5%. In the setting of allogeneic transplant, the incidence ranges from 3 and 7%. 8 There is no information about the frequency of this syndrome in alternative kinds of transplants, that is, umbilical cord blood transplantation, donor lymphocyte infusions, and in the nonablative transplant setting.
We examined patients for episodes of DAH over 7 years at the University of Minnesota and diagnosed 23 out of 922 adult patients, for an incidence of 2.5%. We excluded the pediatric population because immediate bronchoscopy is not routinely administered in children as it may be more hazardous than in an adult population. In adults, 2.5% of the patients suffered from DAH, with an incidence of 0.9% in autologous transplant recipients and 5% in allogeneic recipients. 8 When we examined the incidence over time, we found that in 1997 there was a significant increase in DAH with the sibling and unrelated donor populations that had not been recognized in prior years. We found no difference in clinical factors associated with DAH, including peripheral blood progenitor cells or bone marrow, infectious disease prophylaxis, GVHD, use of cytokines or a pretransplant radiation regimen.
When the syndrome was first described in autologous transplant recipients, it was suggested that it could be associated with the rapid and sometimes explosive engraftment accompanying GCSF mobilized peripheral blood stem cells. 9 Rapid rise in the neutrophil counts were postulated to result in lung damage. 10 In the University of Minnesota series, over 1/3 of patients were still neutropenic at the onset of DAH. Other series have shown that more than 2% neutrophils in the bronchoalveolar lavage is associated with a higher risk of developing DAH. 10 Similarly, a higher bronchitis index, or erythema of the airways, is associated with DAH. A few patients presenting with a clinical syndrome of DAH resemble those presenting with a respiratory virus infection in the lower respiratory tract.
Management of DAH includes measures to reduce alveolar filling pressure and to reduce pulmonary edema and thereby to improve hemodynamics. Additional treatment for these patients is high-dose corticosteroids, ranging from 250-2000 mg/day starting soon after the onset. Of 23 patients treated in our center (at a median 3 days after onset of respiratory symptoms), 21 went on to require mechanical ventilation and only four of those recovered. Overall, 17 of the 23 patients (74%) died at a median of 39 days after transplant and just over 2 weeks after the development of DAH. Only five of the 23 had GVHD. Use of high-dose steroids as pre-emptive therapy for lung injury could have decreased the severity of acute GVHD in these patients, thereby making the association between DAH and GVHD unclear. Of the six patients who survived more than 1 year later, none of them have had significant pulmonary compromise at follow-up.
The reported survival after DAH is very disappointing. The Nebraska series reported 21% survival. 10 In a review of patients treated at Stanford, Memorial Sloan-Kettering Cancer Center, the University of Nebraska, and the National Heart Lung and Blood Institute, survival was less than 33%. 5, 8 The pathogenesis of DAH remains an evolving issue and various hypotheses are still being considered in its etiology. DAH is a hemorrhagic syndrome, but it is not associated with hemoptysis, which means that the alveolar epithelium is not just leaking fluid but is perforated sufficiently to leak red cells. However, because it is a hemorrhagic syndrome aggressive correction of thrombocytopenia and coagulation disturbances may be helpful. There are case reports and a proposal to use recombinant coagulation factor VIIa as a prothrombotic or hemostatic agent. 11 Owing to its cost and its potential association with systemic thrombosis it has not been well studied in the transplant population. Currently, a randomized, placebo-controlled study of recombinant VIIa is being evaluated in the treatment of hemorrhage in marrow transplant recipients. DAH patients will be included. Identification of occult pathogens remains an important part of the diagnostic evaluation. There are suggestions that HHV-6 or mycoplasma might be associated with DAH, but their recovery from the lower airways does not clarify their role in the etiology of DAH. 12, 13 If DAH is associated with chemotherapy or radiation used as part of the conditioning regimen, then the incidence should be lower after nonablative stem cell transplantation but no data is yet available testing this supposition. As a result of cytokine release, which occurs after conditioning, the use of cytokine antagonists has been proposed as a prophylactic measure. 8 We performed a trial of interleukin-1 receptor antagonist placebo as GVHD prophylaxis and observed no difference in the rates of several pulmonary syndromes.
14 Correlation of the incidence of DAH with differing GVHD prophylaxis regimens remains of interest. Finally, because of the association of DAH with an increased bronchitis index and the recognition of neutrophils in the alveolar lavage, this might be an inflammatory syndrome associated with neutrophil activation resulting from inflammatory pathogens within the alveoli. Further clinical and pathologic investigations will be needed to understand this syndrome and define better approaches to management.
